Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 4, 1998, Pages 885-888

  Chien, Shu Chean ^a   Wong, Frank A ^a   Fowler, Cynthia L ^a   Callery D'Amico, Susan V ^a   Williams, R Rex ^a   Nayak, Ramchandra ^a   Chow, Andrew T ^a  

^a R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN;

ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; DRUG URINE LEVEL; HUMAN; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VOMITING;

EID: 0031956777     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.4.885     Document Type: Article

References (26)

1. Adelglass, J., C. A. DeAbate, P. McElvaine, and C. L. Fowler. 1996. A comparison of levofloxacin and amoxicillin clavulanate for the treatment of acute bacterial sinusitis. Presented at the Infectious Diseases Society of America 34th Annual Meeting, New Orleans, La., 18 to 20 September 1996.
2. Baltch, A. L., R. P. Smith, and W. Ritz. 1995. Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila. Antimicrob. Agents Chemother. 39:1661-1666.
3. Blaser, J., B. B. Stone, M. C. Groner, and S. H. Zinner. 1987. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother. 31:1054-1060.
4. Chien, S.-C., M. C. Rogge, L. G. Gisclon, C. Curtin, F. Wong, J. Natarajan, R. R. Williams, C. L. Fowler, W. K. Cheung, and A. T. Chow. 1997. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob. Agents Chemother. 41:2256-2260.
5. Child, J., D. Mortiboy, J. M. Andrews, A. T. Chow, and R. Wise. 1995. Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. Antimicrob. Agents Chemother. 39:2749-2751.
6. Christ, W., and B. Esch. 1994. Adverse reactions to fluoroquinolones in adults and children. Infect. Dis. Clin. Pract. 3(Suppl. 3):S168-S176.
7. DeAbate, C. A., M. Russell, P. McElvaine, H. Fans, J. Upchurch, C. L. Fowler, E. M. Polak, and N. S. Morgan. 1997. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respir. Care 42:206-213.
8. Drusano, G. L., D. E. Johnson, M. Rosen, and H. C. Standiford. 1993. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37:483-490.
9. Dudley, M. N., H. D. Mandler, D. Gilbert, J. Ericson, K. H. Mayer, and S. H. Zinner. 1987. Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin. Am. J. Med. 82(Suppl. 4A):363-368.
10. Eliopoulos, G. M., C. B. Wennersten, and R. C. Moellering, Jr. 1996. Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria. Diagn. Microbiol. Infect. Dis. 25:35-41.
11. File, T. M., Jr., J. Segreti, L. Dunbar, R. Player, R. R. Williams, C. Kojak, and A. Rubin. 1997. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob. Agents Chemother. 41:1965-1972.
12. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
13. Fu, K. P., B. Foleno, and M. E. Rosenthale. 1992. The postantibiotic suppressive effect of L-ofloxacin, an optically active isomer of ofloxacin. Diagn. Microbiol. Infect. Dis. 15:375-378.
14. Fujimoto, T., and S. Mitsuhashi. 1990. In vitro antibacterial activity of DR-3355, the S-(-) isomer of ofloxacin. Chemotherapy 36:268-276.
15. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed. Marcel Dekker, Inc., New York, N.Y.
16. Goodwin, D. S., H. A. Gallis, A. T. Chow, F. A. Wong, S. C. Flor, and J. A. Bartlett. 1994. Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 38:799-804.
17. Hammerschlag, M. R., K. K. Wumei, and P. M. Roblin. 1992. In vitro activities of azithromycin, clarithromycin, levofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 36:1573-1574.
18. McDonald, P. J., and H. Pruul. 1990. Quinolones and the immune system, p. 107-122. In C. Siporin et al. (ed.), The new generation of quinolones. Marcel Dekker, New York, N.Y.
19. Molitoris, E., H. M. Wexler, and S. M. Finegold. 1996. In vitro activity of levofloxacin against bacteria from skin and soft tissue infections, abstr. E88, p. 97. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
20. Nicols, R. L., J. W. Smith, L. O. Gentry, J. Gezon, T. Campbell, P. Sokol, and R. R. Williams. 1997. Multicenter, randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections. South. Med. J. 90:1193-1200.
21. Page, E. B. 1963. Ordered hypotheses for multiple treatments: a significance test for linear ranks. J. Am. Stat. Assoc. 58:216-230.
22. Peloquin, C. A., T. J. Cumbo, D. E. Nix, M. F. Sands, and J. J. Schentag. 1989. Intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections: impact of plasma concentration, organism MIC, and clinical condition on bacterial eradication. Arch. Intern. Med. 149:2269-2273.
23. Richard, G. A., I. N. Klimberg, C. Fowler, and S. Callery-D'Amico. 1996. A combined analysis of two studies comparing levofloxacin (LVFX) with two other fluoroquinolones for the treatment of acute pyelonephritis (pyelo), abstr. LM3, p. 281. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
24. Smith, I. L., and J. J. Schentag. 1984. Noncompartmental determination of the steady-state volume of distribution during multiple dosing. J. Pharm. Sci. 73:281-282.
25. Une, T., T. Fujimoto, K. Sato, and Y. Osada. 1988. In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob. Agents Chemother. 32: 1336-1340.
26. Wong, F. A., S. J. Juzwin, and S. C. Flor. 1997. Rapid stereospecific high-performance liquid Chromatographic determination of levofloxacin in human plasma and urine. J. Pharm. Biomed. Anal. 15:765-771.